Histaminergic vs bradykinin-mediated angioedema
Distinguishing features and pathway-specific therapy for the two mechanisms of angioedema.
Evidence tier: Guideline-derived.
| Feature | Histaminergic | Bradykinin-mediated |
|---|---|---|
| Hives / itch | Common | Absent |
| Onset / duration | Minutes–hours; shorter | Slower; often 24-72+ h (2-5 days) |
| Triggers | Foods, drugs, stings, idiopathic mast-cell activation | ACE inhibitor, hereditary angioedema, acquired C1-INH deficiency, estrogen, trauma |
| Response to antihistamine / epinephrine / steroid | Often responds | Poor response |
| Pathway-specific therapy | Anaphylaxis → IM epinephrine; otherwise 2nd-gen H1 antihistamine (up to 4×) | HAE: C1-INH concentrate, icatibant, ecallantide, oral sebetralstat (2025); prophylaxis lanadelumab/berotralstat/donidalorsen. ACEi-AE: supportive/airway, icatibant & C1-INH NOT reliably effective (phase 3 negative) |
| Labs | Usually none unless anaphylaxis (acute tryptase) | C4, C1-INH antigen + function, C1q (low in acquired AAE). All normal in HAE-nC1INH → genetic testing (F12, PLG, SERPING1) |
Notes
- In an undifferentiated airway emergency, epinephrine is still given empirically, it is not harmful, just not definitive for bradykinin angioedema.
- Permanently discontinue the ACE inhibitor in ACEi-angioedema; an ARB is the usual replacement (small cross-reactivity risk).
Evidence & citations
- Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema, 2021 revision and update. Allergy. 2022;77(7):1961-1990. PMID 35006617
- Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-1277. PMID 24766875
Clinician decision support. Verify against the cited source. Not a substitute for clinical judgment. 100% on-device; no patient data is stored or transmitted.